RE:RE:RE:RE:RE:Another peer reviewed articleI don't think Resverlogix ever abandoned plaque regressioon as one of the beneficial effects os apabetalone. If you look at the news release and patent cited in
this post you will see that HDL level, statin type and statin dose all defined a responder population for plaque regression. Resverlogix didn't disclose that apabetalone was a BET bromodomain inhibitor until several months after the start of the ASSURE IVUS trial and just before the completion of SUSTAIN. A lot has changed with the disclosed mechansim of action and understanding of the beneficially affected biological pathways since the previous understanding of apabetalone as simply an apo-AI/HDL drug during the design and start of SUSTAIN/ASSURE.
BDAZ